<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">TPX</journal-id>
<journal-id journal-id-type="hwp">sptpx</journal-id>
<journal-id journal-id-type="nlm-ta">Toxicol Pathol</journal-id>
<journal-title>Toxicologic Pathology</journal-title>
<issn pub-type="ppub">0192-6233</issn>
<issn pub-type="epub">1533-1601</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0192623311436186</article-id>
<article-id pub-id-type="publisher-id">10.1177_0192623311436186</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Biomarkers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Giant Cell Tumor of Bonelike Lesion in a <italic>Trp53</italic> Mutant Mouse</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Radaelli</surname>
<given-names>Enrico</given-names>
</name>
<xref ref-type="aff" rid="aff1-0192623311436186">1</xref>
<xref ref-type="aff" rid="aff2-0192623311436186">2</xref>
<xref ref-type="corresp" rid="corresp1-0192623311436186"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rustighi</surname>
<given-names>Alessandra</given-names>
</name>
<xref ref-type="aff" rid="aff3-0192623311436186">3</xref>
<xref ref-type="aff" rid="aff4-0192623311436186">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Scanziani</surname>
<given-names>Eugenio</given-names>
</name>
<xref ref-type="aff" rid="aff1-0192623311436186">1</xref>
<xref ref-type="aff" rid="aff2-0192623311436186">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-0192623311436186">
<label>1</label>Dipartimento di Patologia Animale, Università degli Studi di Milano Via Celoria, Milano, Italy</aff>
<aff id="aff2-0192623311436186">
<label>2</label>Mouse &amp; Animal Pathology Lab, Fondazione Filarete, Viale Ortles, Milano, Italy</aff>
<aff id="aff3-0192623311436186">
<label>3</label>Laboratorio Nazionale CIB (LNCIB), Trieste, Italy</aff>
<aff id="aff4-0192623311436186">
<label>4</label>Dipartimento di Scienze della Vita, Università degli Studi di Trieste, Trieste, Italy</aff>
<author-notes>
<corresp id="corresp1-0192623311436186">Enrico Radaelli, Mouse &amp; Animal Pathology Lab, Fondazione Filarete, Viale Ortles, 22/4, 20139, Milano, Italy; e-mail: <email>enrico.radaelli@unimi.it</email>.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>6</month>
<year>2012</year>
</pub-date>
<volume>40</volume>
<issue>4</issue>
<fpage>675</fpage>
<lpage>681</lpage>
<permissions>
<copyright-statement>© 2012 by The Author(s)</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">Society of Toxicologic Pathology</copyright-holder>
</permissions>
<abstract>
<p>Giant cell tumor of bone (GCTB) is a common primary neoplasm of bone characterized by distinctive clinicopathological features. GCTB is exceedingly rare in nonhuman species, and it has been sporadically reported in cats, dogs, rats, and birds. This report describes a primary murine bone tumor that shares striking clinicopathological similarities with human GCTB. The neoplasm occurred in a 71-week-old C57BL/6 mouse heterozygous for the specific <italic>Trp53</italic> R172H point mutation. Grossly, the tumor presented as a mono-ostotic nodular mass arising from the distal metaphysis of the right femur. Microscopically, the affected bone was effaced by an osteolytic neoplasm with focal infiltrations into the surrounding tissues. Similarly to what was reported for human GCTB, the murine neoplasm consisted of 3 main cell populations: (1) bundles of pleomorphic spindle-shaped mononuclear cells displaying an indefinite mesenchymal histogenesis with immunohistochemical expression of vimentin and smooth muscle actin, (2) scattered multinucleated giant cells exhibiting osteoclast differentiation with prominent tartrate-resistant acid phosphatase activity and immunoreactivity for monocyte/macrophage markers including CD45 and lysozyme, and (3) scattered round mononuclear cells consistent with activated macrophages and expressing CD45, lysozyme, and F4/80. Based on these morphological and immunohistological results, the murine bone tumor described in this study has been putatively classified as GCTB.</p>
</abstract>
<kwd-group>
<kwd>mouse</kwd>
<kwd>multinucleated giant cell</kwd>
<kwd>osteoclast precursors</kwd>
<kwd>primary bone tumor</kwd>
<kwd>spindle-shaped mononuclear cells</kwd>
<kwd>
<italic>Tpr53</italic> mutation.</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>With the exception of osteomas in CF-1 and OF-1 outbred strains and osteosarcomas in nonobese diabetic (NOD) and NOD-derived mice, spontaneous primary bone tumors are exceedingly rare in most strains of laboratory mice (<xref ref-type="bibr" rid="bibr10-0192623311436186">Charles and Turusov 1974</xref>; <xref ref-type="bibr" rid="bibr17-0192623311436186">Kavirayani and Foreman 2010</xref>; <xref ref-type="bibr" rid="bibr18-0192623311436186">Kavirayani, Sundberg, and Foreman 2012</xref>; <xref ref-type="bibr" rid="bibr39-0192623311436186">Wilson, Hauser, and Ryffel 1985</xref>). Nevertheless, the recent advent of high-throughput transgenic and gene-targeting technologies has led to the development of innumerable genetically engineered mouse (GEM) models that both phenotypically and genotypically recapitulate the most salient pathobiological features of specific categories of skeletal tumors in humans (<xref ref-type="bibr" rid="bibr18-0192623311436186">Kavirayani, Sundberg, and Foreman 2012</xref>).</p>
<p>Giant cell tumor of bone (GCTB) stands among those human bone tumors for which a murine equivalent has never been described neither as spontaneous lesion nor as GEM or experimentally induced model. In humans, GCTB is a benign tumor that generally arises from the meta-epiphysis of long bones (distal femur and proximal tibia in particular). GCTB accounts for approximately 5% of primary bone tumors and 20% of benign bone tumors. Females are slightly more affected than males, and the majority of patients are in their 20s to 50s (<xref ref-type="bibr" rid="bibr22-0192623311436186">Mendenhall et al. 2006</xref>; <xref ref-type="bibr" rid="bibr33-0192623311436186">Thomas and Skubitz 2009</xref>; <xref ref-type="bibr" rid="bibr38-0192623311436186">Werner 2006</xref>). Most GCTBs are solitary; however, multicentric tumors do occur, especially in the distal extremities (<xref ref-type="bibr" rid="bibr11-0192623311436186">Dhillon and Prasad 2007</xref>). Despite its benign designation, GCTB often exhibits local aggressiveness with remarkable bone destruction and invasion of adjacent soft tissues. Further underlying its unpredictable behavior, treatment by conservative local surgery is associated with a recurrence rate of approximately 30% to 60%, and a small subset of apparently benign GCTBs give rise to pulmonary metastases (<xref ref-type="bibr" rid="bibr1-0192623311436186">Alberghini et al. 2010</xref>; <xref ref-type="bibr" rid="bibr4-0192623311436186">Becker et al. 2008</xref>; <xref ref-type="bibr" rid="bibr9-0192623311436186">Campanacci et al. 1987</xref>; <xref ref-type="bibr" rid="bibr21-0192623311436186">Liu and Wang 1998</xref>; <xref ref-type="bibr" rid="bibr27-0192623311436186">O’Donnell et al. 1994</xref>).</p>
<p>Histologically, GCTB consists of a mixture of round and spindle mononuclear cells, scattered among which are large multinucleated osteoclast-like giant cells. The exact histogenesis of GCTB is still controversial (<xref ref-type="bibr" rid="bibr24-0192623311436186">Morgan et al. 2005</xref>). Although historically classified as “osteoclastoma” and currently referred to as “giant cell tumor,” osteoclast-like giant cells do not represent the neoplastic component of the neoplasm. In this regard, recent studies indicate that stromal spindle cells, the major component of the mononuclear cell population, are the true neoplastic elements of GCTB (<xref ref-type="bibr" rid="bibr22-0192623311436186">Mendenhall et al. 2006</xref>; <xref ref-type="bibr" rid="bibr31-0192623311436186">Salerno et al. 2008</xref>; <xref ref-type="bibr" rid="bibr42-0192623311436186">Wülling et al. 2001</xref>; <xref ref-type="bibr" rid="bibr43-0192623311436186">Yasko 2002</xref>; <xref ref-type="bibr" rid="bibr45-0192623311436186">Zheng et al. 2001</xref>).</p>
<p>GCTB is exceedingly rare in nonhuman species, and so far it has been only sporadically described in cats, dogs, rats, and birds (<xref ref-type="bibr" rid="bibr2-0192623311436186">Amann et al. 2007</xref>; <xref ref-type="bibr" rid="bibr5-0192623311436186">Berg, Gliatto, and Wallace 1990</xref>; <xref ref-type="bibr" rid="bibr12-0192623311436186">Ferreras et al. 2005</xref>; <xref ref-type="bibr" rid="bibr15-0192623311436186">Imai et al. 1998</xref>; <xref ref-type="bibr" rid="bibr34-0192623311436186">Trigo, Leathers, and Brobst 1983</xref>; <xref ref-type="bibr" rid="bibr35-0192623311436186">Walsh and Rhodes 1995</xref>). This study aims at describing the pathological and immunohistochemical features of a GCTB-like lesion that occurred in a 71-week-old C57BL/6 female mouse harboring a <italic>Trp53</italic> (p53) mutant allele with a G-to-A substitution at nucleotide 515. Mice belonging to this specific strain were developed by <xref ref-type="bibr" rid="bibr19-0192623311436186">Lang et al. (2004)</xref> using a knock-in strategy and currently represent one of the most reliable animal models mimicking human Li-Fraumeni syndrome, both genotypically and phenotypically (<xref ref-type="bibr" rid="bibr14-0192623311436186">Girardini et al. 2011</xref>). The mouse reported here was included in a cohort of 19 animals, for which the tumor spectrum and frequency are summarized in <xref ref-type="table" rid="table1-0192623311436186">Table 1</xref>.</p>
<table-wrap id="table1-0192623311436186" position="float">
<label>Table 1.</label>
<caption>
<p>Tumor spectrum and frequency in a cohort of 19 C57BL/6 mice heterozygous for the specific Trp53 R172H point mutation (<xref ref-type="bibr" rid="bibr19-0192623311436186">Lang et al. 2004</xref>).</p>
</caption>
<graphic alternate-form-of="table1-0192623311436186" xlink:href="10.1177_0192623311436186-table1.tif"/>
<table>
<thead>
<tr>
<th>Tumor phenotype</th>
<th>No. of tumors in 19 mice</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="2">Lymphoid hematopoietic neoplasms</td>
</tr>
<tr>
<td> Precursor T-cell lymphoblastic lymphoma</td>
<td>1</td>
</tr>
<tr>
<td> Multicentric nodal and/or splenic B-cell  lymphoma</td>
<td>3</td>
</tr>
<tr>
<td colspan="2">Nonlymphoid hematopoietic neoplasms</td>
</tr>
<tr>
<td> Histiocytic sarcoma</td>
<td>2</td>
</tr>
<tr>
<td> Myeloid leukemia</td>
<td>1</td>
</tr>
<tr>
<td colspan="2">Carcinomas</td>
</tr>
<tr>
<td> Cholangiocarcinoma</td>
<td>1</td>
</tr>
<tr>
<td> Hepatocarcinoma</td>
<td>1</td>
</tr>
<tr>
<td> Intestinal adenocarcinoma</td>
<td>1</td>
</tr>
<tr>
<td> Undifferentiated prostatic carcinoma</td>
<td>1</td>
</tr>
<tr>
<td> Undifferentiated mammary carcinoma</td>
<td>1</td>
</tr>
<tr>
<td> Urothelial carcinoma</td>
<td>1</td>
</tr>
<tr>
<td colspan="2">Sarcomas</td>
</tr>
<tr>
<td> Osteosarcoma</td>
<td>2</td>
</tr>
<tr>
<td> Hemangiosarcoma</td>
<td>2</td>
</tr>
<tr>
<td> Undifferentiated soft-tissue sarcoma</td>
<td>3</td>
</tr>
<tr>
<td colspan="2">Others</td>
</tr>
<tr>
<td> Pituitary adenoma</td>
<td>1</td>
</tr>
<tr>
<td> Giant cell tumor of bone-like lesion</td>
<td>1</td>
</tr>
<tr>
<td>Total no. of tumors</td>
<td>22</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Clinically, the mouse presented with hunched posture, labored breathing, and right paraparesis associated with marked nodular swelling of the right thigh. The mouse eventually became moribound and was humanely euthanized by CO<sub>2</sub> asphyxiation followed by atlanto-occipital dislocation. A complete necropsy was performed, and thymus, lungs, heart, spleen, liver, pancreas, kidneys, and mesenteric lymph nodes were collected and immediately fixed in 10% neutral buffered formalin (NBF). The affected hind limb was removed in toto and decalcified for 20 days in a supersaturated solution of EDTA in 10% NBF. Sampled organs/tissues were routinely processed for histological examination and embedded in paraffin blocks. Four-micrometer-thick sections obtained from these blocks were then stained with hematoxylin and eosin and evaluated under a light microscope. Serial sections from the nodular lesion in the right thigh were also obtained for further immunohistochemical analyses, picrosyrius red staining, and tartrate-resistant acid phosphatase (TRAP) activity (catalog 387A, Sigma-Aldrich, St. Louis, MO). Details concerning the panel of immunohistochemical stains applied are summarized in <xref ref-type="table" rid="table2-0192623311436186">Table 2</xref>.</p>
<table-wrap id="table2-0192623311436186" position="float">
<label>Table 2.</label>
<caption>
<p>Details concerning primary antibodies and procedures used for the immunohistochemical examination of the primary murine bone tumor reported in this study.</p>
</caption>
<graphic alternate-form-of="table2-0192623311436186" xlink:href="10.1177_0192623311436186-table2.tif"/>
<table>
<thead>
<tr>
<th>Antigen</th>
<th>Primary antibody</th>
<th>Source</th>
<th>Antigen retrieval</th>
<th>Working dilution</th>
<th>Incubation time</th>
<th>Detection system</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD31 (PECAM)</td>
<td>SZ31 Rat mon<sup><xref ref-type="table-fn" rid="table-fn1-0192623311436186">a</xref></sup>
</td>
<td>Dianova</td>
<td>HIER<sup><xref ref-type="table-fn" rid="table-fn4-0192623311436186">d</xref></sup>
</td>
<td>1:50</td>
<td>1 h RT<sup><xref ref-type="table-fn" rid="table-fn7-0192623311436186">g</xref></sup>
</td>
<td>ABC<sup><xref ref-type="table-fn" rid="table-fn9-0192623311436186">i</xref></sup>
</td>
</tr>
<tr>
<td>CD45</td>
<td>30-F11 Rat mon</td>
<td>BD-Pharmigen</td>
<td>HIER</td>
<td>1:150</td>
<td>1 h RT</td>
<td>ABC</td>
</tr>
<tr>
<td>Collagen I</td>
<td>Ab34710 Rb poly<sup><xref ref-type="table-fn" rid="table-fn2-0192623311436186">b</xref></sup>
</td>
<td>Abcam</td>
<td>N/A<sup><xref ref-type="table-fn" rid="table-fn5-0192623311436186">e</xref></sup>
</td>
<td>1:50</td>
<td>1 h RT</td>
<td>ABC</td>
</tr>
<tr>
<td>Desmin</td>
<td>Y66 1466-1 Rb mon<sup><xref ref-type="table-fn" rid="table-fn3-0192623311436186">c</xref></sup>
</td>
<td>Epitomics</td>
<td>HIER</td>
<td>1:200</td>
<td>1 h RT</td>
<td>ABC</td>
</tr>
<tr>
<td>F4/80</td>
<td>Cl: A3-1 MCA497G Rat mon</td>
<td>Serotec</td>
<td>Enzymatic digestion<sup><xref ref-type="table-fn" rid="table-fn6-0192623311436186">f</xref></sup>
</td>
<td>1:200</td>
<td>1 h RT</td>
<td>ABC</td>
</tr>
<tr>
<td>Glial fibrillary acidic protein</td>
<td>Z0334 Rb poly</td>
<td>Dako</td>
<td>HIER</td>
<td>1:1500</td>
<td>1 h RT</td>
<td>ABC</td>
</tr>
<tr>
<td>Ki-67</td>
<td>#RM-9106-S Rb mon</td>
<td>LabVision (Thermo Scientific)</td>
<td>HIER</td>
<td>1:150</td>
<td>1 h RT</td>
<td>EnVision<sup><xref ref-type="table-fn" rid="table-fn10-0192623311436186">j</xref></sup>
</td>
</tr>
<tr>
<td>Lysozyme</td>
<td>A0099 Rb poly</td>
<td>Dako</td>
<td>Enzymatic digestion</td>
<td>1:1000</td>
<td>40′ at 37°C<sup><xref ref-type="table-fn" rid="table-fn8-0192623311436186">h</xref></sup>
</td>
<td>ABC</td>
</tr>
<tr>
<td>S100</td>
<td>Z0311</td>
<td>Dako</td>
<td>HIER</td>
<td>1:1000</td>
<td>1 h RT</td>
<td>ABC</td>
</tr>
<tr>
<td>Smooth muscle actin</td>
<td>#RB-9010 Rb poly</td>
<td>LabVision (Thermo Scientific)</td>
<td>HIER</td>
<td>1:200</td>
<td>1 h RT</td>
<td>ABC</td>
</tr>
<tr>
<td>Vimentin</td>
<td>EPR3776 Rb mon</td>
<td>Epitomics</td>
<td>HIER</td>
<td>1:500</td>
<td>1 h RT</td>
<td>ABC</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0192623311436186">
<p>
<sup>a</sup> Rat monoclonal.</p>
</fn>
<fn id="table-fn2-0192623311436186">
<p>
<sup>b</sup> Rabbit polyclonal.</p>
</fn>
<fn id="table-fn3-0192623311436186">
<p>
<sup>c</sup> Rabbit monoclonal.</p>
</fn>
<fn id="table-fn4-0192623311436186">
<p>
<sup>d</sup> Heat-induced epitope retrival, 2100 (Retriever, PickCell Labs, Lelystad, The Netherlands), 0.01 mol/L citrate buffer pH = 6.0 (Diapath SpA, Martinengo, Bergamo, Italy).</p>
</fn>
<fn id="table-fn5-0192623311436186">
<p>
<sup>e</sup> No antigen retrieval used.</p>
</fn>
<fn id="table-fn6-0192623311436186">
<p>
<sup>f</sup> Digest-all™3 Pepsin solution RTU (Invitrogen Corporation, Camarillo, CA).</p>
</fn>
<fn id="table-fn7-0192623311436186">
<p>
<sup>g</sup> One hour at room temperature.</p>
</fn>
<fn id="table-fn8-0192623311436186">
<p>
<sup>h</sup> Forty minutes at 37°C.</p>
</fn>
<fn id="table-fn9-0192623311436186">
<p>
<sup>i</sup> Avidin-biotin complex (Vectastain Elite ABC kit PK-6100, Vector Laboratories Inc., Burlingame, CA).</p>
</fn>
<fn id="table-fn10-0192623311436186">
<p>
<sup>j</sup> Dako EnVision™ system (DakoCytomation, Glostrup, Denmark).</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Procedures involving animals and their care conformed to institutional guidelines in compliance with national (D.L.vo 116/92 and following additions) and international (EEC Council Directive 86/609, OJ L 358,1,12-12-1987; NIH Guide for the Care and Use of Laboratory Animals, U.S. National Research Council 1996) laws and policies.</p>
<p>At necropsy, the swelled right thigh turned out to be affected by a whitish and solid nodular mass measuring approximately 12 × 8 × 6 mm. The lesion arose from the mediocaudal aspect of the distal metaphysis of the right femur and appeared to be well demarcated from the surrounding musculofascial tissues. Additional gross changes included moderate splenomegaly and mild mesenteric lymphadenomegaly.</p>
<p>Microscopically, the affected portion of the femur was effaced by a densely cellular osteolytic neoplasm that, apart from few satellite nodules and focal infiltrative extensions into the surrounding soft tissues, appeared to be well demarcated, partially capsulated with an expansile growth pattern and compression atrophy of the adjacent skeletal muscles (<xref ref-type="fig" rid="fig1-0192623311436186">Figure 1A</xref>). Tumors consisted of short irregular bundles of pleomorphic spindle-shaped mononuclear cells (SMCs) interspersed with numerous large multinucleated giant cells (MGCs). This latter cell population often displayed an osteoclast-like morphology with dendritic outlines, a moderate amount of dense eosinophilic cytoplasm, and up to 50 small uniform oval nuclei clustered in the center of the cell (<xref ref-type="fig" rid="fig1-0192623311436186">Figure 1A</xref>, inset). Findings of cellular atypia including marked anisocytosis, anisokaryosis, karyomegaly, cytomegaly, hyperchromasia, multiple irregular nucleoli, and numerous and often bizarre mitotic figures (8-12 × hpf) were almost exclusively observed in a subset of SMCs. Individual or small aggregates of medium-sized round mononuclear cells (RMCs) morphologically consistent with activated macrophages were also scattered throughout the tumor. As highlighted by picrosyrius red stain, the neoplasm was supported by a scant amount of stroma characterized by a combination of delicate fibrovascular septa and broad bundles of fibrous connective tissue. The severe tumor-associated osteolysis was occasionally accompanied by a minimal amount of reactive woven bone formation.</p>
<fig id="fig1-0192623311436186" position="float">
<label>Figure 1.</label>
<caption>
<p>Giant cell tumor of bonelike lesion in a 71-week-old Trp53 mutant female mouse. Densely cellular heterogeneous tumor that compresses and focally infiltrates the adjacent skeletal muscles; hematoxylin and eosin (H&amp;E) stain, scale bar 200 µm (A). Note the morphology of the scattered intratumoral osteoclast-like multinucleated giant cells; H&amp;E stain, scale bar 100 µm (A, inset). An elevated number of tartrate-resistant acid phosphatase (TRAP)–positive osteoclast-like multinucleated giant cells populate the neoplasm; TRAP histochemistry, scale bar 200 µm (B). Marked CD45 and lysozyme immunoreactivity in the osteoclast-like multinucleated giant cells and in scattered round mononuclear cells morphologically consistent with activated macrophages; note the unstained pleomorphic spindle-shaped mononuclear cells; CD45 and lysozyme immunoperoxidase staining, scale bar 100 µm (C and D, respectively). Scattered bundles of spindle-shaped mononuclear cells are markedly immunoreactive for smooth muscle actin (SMA), SMA immunoperoxidase staining, scale bar 100 µm (E). Ki-67 nuclear expression in the vast majority of pleomorphic spindle-shaped mononuclear cells; note the unstained osteoclast-like multinucleated giant cell; Ki-67 immunoperoxidase staining, scale bar 100 µm (F).</p>
</caption>
<graphic xlink:href="10.1177_0192623311436186-fig1.tif"/>
</fig>
<p>A detailed summary of the histochemical and immunohistochemical features observed in SMCs, MGCs, and RMCs is reported in <xref ref-type="table" rid="table3-0192623311436186">Table 3</xref>. Osteoclast-like MGCs exhibited prominent tartrate-resistant acid phosphatase (TRAP) activity (<xref ref-type="fig" rid="fig1-0192623311436186">Figure 1B</xref>) and consistent immunohistochemical expression of vimentin and histiocytic markers including CD45 (common leukocyte antigen) and lysozyme (<xref ref-type="fig" rid="fig1-0192623311436186">Figures 1C</xref> and D). Few scattered MGCs also displayed weak immunoreactivity for smooth muscle actin (SMA). No TRAP activity or lysozyme and CD45 immunohistochemical expression was identified in SMCs. This latter cell population showed marked and diffuse vimentin immunoreactivity. A subset of SMCs was also strongly positive for SMA (<xref ref-type="fig" rid="fig1-0192623311436186">Figure 1E</xref>). Variable degrees of vimentin, CD45, lysozyme, and F4/80 expression were observed in the intratumoral aggregates of RMCs morphologically consistent with activated macrophages. Ki-67 immunohistochemistry revealed a remarkable number of positive nuclei within the SMC population, whereas a negligible level of Ki-67 expression was evident in MGCs and RMCs (<xref ref-type="fig" rid="fig1-0192623311436186">Figure 1F</xref>). SMCs, MGCs, and RMCs were largely negative for CD31/PECAM, collagen I, glial fibrillary acidic protein, and S100 immunohistochemistry.</p>
<table-wrap id="table3-0192623311436186" position="float">
<label>Table 3.</label>
<caption>
<p>Summary of the histochemical and immunohistochemical phenotype displayed by spindle-shaped mononuclear cells, multinucleated giant cells, and round mononuclear cells populating the murine giant cell tumor of bonelike lesion examined in this study.</p>
</caption>
<graphic alternate-form-of="table3-0192623311436186" xlink:href="10.1177_0192623311436186-table3.tif"/>
<table>
<thead>
<tr>
<th>Stain</th>
<th>Spindle-shaped mononuclear cells</th>
<th>Multinucleated giant cells</th>
<th>Round mononuclear cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD31/PECAM</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>CD45</td>
<td>—</td>
<td>+++ mc</td>
<td>+++ mc</td>
</tr>
<tr>
<td>Collagen I</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Desmin</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>F4/80</td>
<td>—</td>
<td>—</td>
<td>++ mc</td>
</tr>
<tr>
<td>Glial fibrillary acidic protein</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Ki-67</td>
<td>+++ n</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Lysozyme</td>
<td>—</td>
<td>+++ c</td>
<td>++ c</td>
</tr>
<tr>
<td>S100</td>
<td>+ nc</td>
<td>—</td>
<td>+ nc</td>
</tr>
<tr>
<td>Smooth muscle actin</td>
<td>++ c</td>
<td>+ c</td>
<td>—</td>
</tr>
<tr>
<td>Tartrate-resistant acid phosphatase</td>
<td>—</td>
<td>+++ c</td>
<td>—</td>
</tr>
<tr>
<td>Vimentin</td>
<td>+++ c</td>
<td>+++ c</td>
<td>+++ c</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn11-0192623311436186">
<p>(—) no detectable immunoreactivity/stain; (+) immunoreactivity/stain accounting for less than 10% of the considered cell population; (++) immunoreactivity/stain comprised between 20% and 60% of the considered cell population; (+++) immunoreactivity/stain accounting for more than 60% of the considered cell population; c = cytoplasmic immunoreactivity; mc = membranous to cytoplasmic immunoreactivity; n = nuclear immunoreactivity; nc = nuclear to cytoplasmic immunoreactivity.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Additional histopathologic changes observed in the other organs/tissues included splenic low-grade marginal zone lymphoma and marked sinus histiocytosis of the mesenteric lymph nodes.</p>
<p>This report describes a primary murine bone tumor that shares striking clinicopathological similarities with human GCTB. The neoplasm presented as a mono-ostotic nodular proliferation arising from the distal femoral metaphysis. Interestingly, femoral metaphysis is one of the most common sites of origin for solitary GCTB in humans (<xref ref-type="bibr" rid="bibr22-0192623311436186">Mendenhall et al. 2006</xref>). In this context, it should be also recalled that the only GCTB so far described in a laboratory rodent (i.e., a 98-week-old male F344 rat) arose from the distal end of the femur (<xref ref-type="bibr" rid="bibr15-0192623311436186">Imai et al. 1998</xref>). Based on the morphological and immunohistological results obtained, the bone tumor described in this study appears to be composed of the same heterogeneous cell populations typically observed in human GCTB.</p>
<p>SMCs were the principal cell type observed in the murine GCTB-like lesion. Consistent with the putative origin of human SMCs from multipotent mesenchymal stem cells (<xref ref-type="bibr" rid="bibr29-0192623311436186">Robinson, Segal, and Nevo 2002</xref>-2003; <xref ref-type="bibr" rid="bibr30-0192623311436186">Roux et al. 2002</xref>; <xref ref-type="bibr" rid="bibr38-0192623311436186">Werner 2006</xref>; <xref ref-type="bibr" rid="bibr42-0192623311436186">Wülling et al. 2001</xref>; <xref ref-type="bibr" rid="bibr41-0192623311436186">Wülling, Delling, and Kaiser 2003</xref>), murine SMCs displayed an indefinite mesenchymal histogenesis being positive only for vimentin and, to a lesser degree, SMA. It is now well established that SMCs represent the true neoplastic component of GCTB. The same could be assumed also for the bone tumor described in this report as features of cellular atypia, aberrant mitosis, and abnormally high proliferative activity were limited to the SMC component. Similar anaplastic changes and increased proliferative activity are well documented also in human GCTB, where they are considered hallmarks of sarcomatous transformation and “dedifferentiation,” carrying a dismal prognosis in term of metastatic potential (<xref ref-type="bibr" rid="bibr6-0192623311436186">Bertoni, Bacchini, and Staals 2003</xref>; <xref ref-type="bibr" rid="bibr13-0192623311436186">Forsyth and Hogendoorn 2003</xref>; <xref ref-type="bibr" rid="bibr28-0192623311436186">Reid, Banerjee, and Sciot 2002</xref>). SMA immunoreactivity in the murine GCTB-like lesion further supports this view since the expression of this marker has been specifically reported in primary GCTBs with high recurrence and/or metastatic potential (<xref ref-type="bibr" rid="bibr1-0192623311436186">Alberghini et al., 2010</xref>). The exact biological significance of SMA expression by SMCs from GCTB is still unclear and a matter of controversy. It may indicate the acquisition of a myofibroblastic phenotype, as suggested by some studies (<xref ref-type="bibr" rid="bibr15-0192623311436186">Imai et al. 1998</xref>; <xref ref-type="bibr" rid="bibr36-0192623311436186">Watanabe et al. 1997</xref>). However, other authors report that myofibroblastic differentiation in SMCs is unlikely as they lack key structures typical of both reactive and transformed myofibroblasts, including fibronexus (<xref ref-type="bibr" rid="bibr37-0192623311436186">Watanabe et al. 2000</xref>). It must be also considered that transformed multipotent mesenchymal stem cells (the progenitor cells SMCs are supposed to derive from) have been demonstrated to express SMA and display a myofibroblastic-like phenotype under the influence of a wide plethora of oncogenic stimuli (<xref ref-type="bibr" rid="bibr8-0192623311436186">Burns et al. 2008</xref>; <xref ref-type="bibr" rid="bibr16-0192623311436186">Jeong et al. 2011</xref>). Malignant transformation in GCTB has been also frequently correlated with p53 mutations, and in this context, it should be emphasized that the affected mouse was genetically manipulated to carry a point mutant p53 allele (<xref ref-type="bibr" rid="bibr26-0192623311436186">Oda et al. 2001</xref>; <xref ref-type="bibr" rid="bibr40-0192623311436186">Wu et al. 1997</xref>).</p>
<p>MGCs observed in the murine GCTB-like lesion confirmed their actual osteoclast differentiation exhibiting prominent TRAP activity and consistent immunohistochemical expression for markers of the monocyte/macrophage lineage including CD45 and lysozyme. Both CD45 and lysozyme have been previously reported to specifically identify the MGCs populating GCTB (Aqel, Pringle, and Horton <xref ref-type="bibr" rid="bibr3-0192623311436186">1988</xref>; <xref ref-type="bibr" rid="bibr7-0192623311436186">Bouropoulou, Kontogeorgos, and Manika 1985</xref>; <xref ref-type="bibr" rid="bibr12-0192623311436186">Ferreras et al, 2005</xref>; <xref ref-type="bibr" rid="bibr46-0192623311436186">Fornasier et al. 1996</xref>; <xref ref-type="bibr" rid="bibr24-0192623311436186">Morgan et al. 2005</xref>; <xref ref-type="bibr" rid="bibr30-0192623311436186">Roux et al. 2002</xref>).</p>
<p>Immunohistochemical examination of the murine GCTB-like lesion also highlighted the presence of multiple intratumoral aggregates of activated macrophages in the form of RMCs with variable degrees of vimentin, CD45, lysozyme, and F4/80 expression. It has been widely documented that GCTB is populated by a variable number of ovoid mononuclear cells phenotypically consistent with activated monocytes/macrophages (<xref ref-type="bibr" rid="bibr13-0192623311436186">Forsyth and Hogendoorn 2003</xref>; <xref ref-type="bibr" rid="bibr22-0192623311436186">Mendenhall et al. 2006</xref>; <xref ref-type="bibr" rid="bibr28-0192623311436186">Reid, Banerjee, and Sciot 2002</xref>; <xref ref-type="bibr" rid="bibr33-0192623311436186">Thomas and Skubitz 2009</xref>; <xref ref-type="bibr" rid="bibr38-0192623311436186">Werner 2006</xref>). Beside the expression of typical lineage-specific markers (e.g. CD68), GCTB-associated monocytes/macrophages have been demonstrated to represent osteoclast precursors that, in response to a paracrine-juxtacrine stimulus likely generated by SMCs, are recruited in the site of tumor development and differentiate into osteoclasts. In this context, GCTB-associated osteoclastogenesis has been delineated at the molecular level, highlighting how the interaction between receptor activator of nuclear factor κ B and its ligand expressed on recruited monocyte/macrophages and SMCs, respectively, is a key to the formation and maturation of osteoclasts (<xref ref-type="bibr" rid="bibr30-0192623311436186">Roux et al. 2002</xref>; <xref ref-type="bibr" rid="bibr38-0192623311436186">Werner 2006</xref>; <xref ref-type="bibr" rid="bibr45-0192623311436186">Zheng et al. 2001</xref>). Other humoral factors released by SMCs such as stromal cell derived factor-1, macrophage chemoattractant protein-1, and macrophage colony-stimulating factor proved to play a critical role in the production, recruitment, and fusion of osteoclast precursors (<xref ref-type="bibr" rid="bibr20-0192623311436186">Liao et al. 2005</xref>; <xref ref-type="bibr" rid="bibr23-0192623311436186">Miyamoto et al. 2000</xref>; <xref ref-type="bibr" rid="bibr44-0192623311436186">Zheng et al. 1998</xref>).</p>
<p>From a pathobiological perspective, it is unclear whether the same molecular mechanisms underlying GCTB in humans are also responsible for the development of the primary murine bone tumor described in this study. For this reason, the neoplasm has been cautiously defined as GCTB-like lesions on a morphophenotypic basis.</p>
<p>The main differential diagnoses considered for this case of murine GCTB-like lesion were rhabdomyosarcoma, histiocytic sarcoma, and giant cell-rich osteosarcoma. However, since both MGCs and SMCs failed to express immunohistochemical markers indicative of muscular (i.e., desmin), histiocytic (i.e., F4/80), and osteoblastic (i.e., collagen I) differentiation, these alternative diagnostic hypotheses were ruled out. In addition, standard histology combined with collagen I and picrosyrius red stain did not evidence any intratumoral accumulation of extracellular matrix compatible with osteoid. In this regard, the complete lack of intratumoral deposits of osteoid is generally regarded as an important diagnostic feature to differentiate GCTB from giant cell-rich osteosarcoma (<xref ref-type="bibr" rid="bibr25-0192623311436186">Negrin et al. 2006</xref>; <xref ref-type="bibr" rid="bibr32-0192623311436186">Sato et al. 1996</xref>).</p>
<p>In conclusion, the unusual primary murine bone tumor described in this study has been putatively classified as GCTB since it recapitulates many of the morphological and immunohistological features of the equivalent human condition. The accurate definition of this rare spontaneous tumor in mice may eventually stimulate the design and conduction of experiments aimed at establishing an animal model that may serve as a tool to dissect the molecular mechanisms underlying the onset and progression of GCTB and to test novel therapeutic strategies. This case report should also reinforce the awareness of the possible occurrence of previously undescribed bone tumor phenotypes in GEM models in which the function of crucial gatekeeper tumor suppressor genes (e.g., <italic>Tpr53</italic>) has been severely compromised.</p>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>We gratefully acknowledge Drs. Marco Losa, Camilla Recordati, and Vittoria Castiglioni of the Mouse &amp; Animal Pathology Lab for their assistance with immunohistological procedures.</p>
</ack>
<fn-group>
<fn fn-type="conflict" id="fn1-0192623311436186">
<p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-0192623311436186">
<p>The authors received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<glossary content-type="abbr">
<title>Abbreviations</title>
<def-list>
<def-item>
<term id="term1-0192623311436186">GCTB</term>
<def>
<p>giant cell tumor of bone</p>
</def>
</def-item>
<def-item>
<term id="term2-0192623311436186">GEM</term>
<def>
<p>genetically engineered mouse</p>
</def>
</def-item>
<def-item>
<term id="term3-0192623311436186">MGCs</term>
<def>
<p>multinucleated giant cells</p>
</def>
</def-item>
<def-item>
<term id="term4-0192623311436186">NBF</term>
<def>
<p>neutral buffered formalin</p>
</def>
</def-item>
<def-item>
<term id="term5-0192623311436186">NOD</term>
<def>
<p>nonobese diabetic</p>
</def>
</def-item>
<def-item>
<term id="term6-0192623311436186">RMCs</term>
<def>
<p>round mononuclear cells</p>
</def>
</def-item>
<def-item>
<term id="term7-0192623311436186">SMA</term>
<def>
<p>smooth muscle actin</p>
</def>
</def-item>
<def-item>
<term id="term8-0192623311436186">SMCs</term>
<def>
<p>spindle-shaped mononuclear cells</p>
</def>
</def-item>
<def-item>
<term id="term9-0192623311436186">TRAP</term>
<def>
<p>tartrate-resistant acid phosphatase</p>
</def>
</def-item>
<def-item>
<term id="term10-0192623311436186">TRP53</term>
<def>
<p>transformation related protein 53</p>
</def>
</def-item>
</def-list>
</glossary>
<ref-list>
<title>References</title>
<ref id="bibr1-0192623311436186">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alberghini</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kliskey</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Krenacs</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Picci</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Kindblom</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Forsyth</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Athanasou</surname>
<given-names>N. A.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Morphological and immunophenotypic features of primary and metastatic giant cell tumour of bone</article-title>. <source>Virchows Arch</source> <volume>456</volume>, <fpage>97</fpage>–<lpage>103</lpage>.</citation>
</ref>
<ref id="bibr2-0192623311436186">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amann</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Meij</surname>
<given-names>B. P.</given-names>
</name>
<name>
<surname>Westerhof</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Kik</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lumeij</surname>
<given-names>J. T.</given-names>
</name>
<name>
<surname>Schoemaker</surname>
<given-names>N. J.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Giant cell tumor of the bone in a scarlet macaw (<italic>Ara macao</italic>)</article-title>. <source>Avian Dis</source> <volume>51</volume>, <fpage>146</fpage>–<lpage>49</lpage>.</citation>
</ref>
<ref id="bibr3-0192623311436186">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aqel</surname>
<given-names>N. M.</given-names>
</name>
<name>
<surname>Pringle</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Horton</surname>
<given-names>M. A.</given-names>
</name>
</person-group> (<year>1988</year>). <article-title>Cellular heterogeneity in giant cell tumour of bone (osteoclastoma): An immunohistological study of 16 cases</article-title>. <source>Histopathology</source> <volume>13</volume>, <fpage>675</fpage>–<lpage>85</lpage>.</citation>
</ref>
<ref id="bibr4-0192623311436186">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Becker</surname>
<given-names>W. T.</given-names>
</name>
<name>
<surname>Dohle</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bernd</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Braun</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cserhati</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Enderle</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hovy</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Matejovsky</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Szendroi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Trieb</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Tunn</surname>
<given-names>P. U.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Local recurrence of giant cell tumor of bone after intralesional treatment with and without adjuvant therapy</article-title>. <source>J Bone Joint Surg Am</source> <volume>90</volume>, <fpage>1060</fpage>–<lpage>67</lpage>.</citation>
</ref>
<ref id="bibr5-0192623311436186">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berg</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gliatto</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Wallace</surname>
<given-names>M. K.</given-names>
</name>
</person-group> (<year>1990</year>) <article-title>Giant cell tumor of the accessory carpal bone in a dog</article-title>. <source>J Am Vet Med Assoc</source> <volume>197</volume>, <fpage>883</fpage>–<lpage>85</lpage>.</citation>
</ref>
<ref id="bibr6-0192623311436186">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bertoni</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Bacchini</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Staals</surname>
<given-names>E. L.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>Malignancy in giant cell tumor of bone</article-title>. <source>Cancer</source> <volume>97</volume>, <fpage>2520</fpage>–<lpage>29</lpage>.</citation>
</ref>
<ref id="bibr7-0192623311436186">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bouropoulou</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Kontogeorgos</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Manika</surname>
<given-names>Z.</given-names>
</name>
</person-group> (<year>1985</year>). <article-title>A histological and immunoenzymatic study on the histogenesis of “giant cell tumor of bones.”</article-title> <source>Pathol Res Pract</source> <volume>180</volume>, <fpage>61</fpage>–<lpage>67</lpage>.</citation>
</ref>
<ref id="bibr8-0192623311436186">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burns</surname>
<given-names>J. S.</given-names>
</name>
<name>
<surname>Abdallah</surname>
<given-names>B. M.</given-names>
</name>
<name>
<surname>Schrøder</surname>
<given-names>H. D.</given-names>
</name>
<name>
<surname>Kassem</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>The histopathology of a human mesenchymal stem cell experimental tumor model: Support for an hMSC origin for Ewing’s sarcoma?</article-title> <source>Histol Histopathol</source> <volume>23</volume>, <fpage>1229</fpage>–<lpage>40</lpage>.</citation>
</ref>
<ref id="bibr9-0192623311436186">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Campanacci</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Baldini</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Boriani</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sudanese</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>1987</year>) <article-title>Giant-cell tumor of bone</article-title>. <source>J Bone Joint Surg Am</source> <volume>69</volume>, <fpage>106</fpage>–<lpage>14</lpage>.</citation>
</ref>
<ref id="bibr10-0192623311436186">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Charles</surname>
<given-names>R. T.</given-names>
</name>
<name>
<surname>Turusov</surname>
<given-names>V. S.</given-names>
</name>
</person-group> (<year>1974</year>). <article-title>Bone tumours in CF-1 mice</article-title>. <source>Lab Anim</source> <volume>8</volume>, <fpage>137</fpage>–<lpage>44</lpage>.</citation>
</ref>
<ref id="bibr11-0192623311436186">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dhillon</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Prasad</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Multicentric giant cell tumour of bone</article-title>. <source>Acta Orthop Belg</source> <volume>73</volume>, <fpage>289</fpage>–<lpage>99</lpage>.</citation>
</ref>
<ref id="bibr12-0192623311436186">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferreras</surname>
<given-names>M. C.</given-names>
</name>
<name>
<surname>Fuertes</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pérez</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Benavides</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>García-Pariente</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Reyes</surname>
<given-names>L. E.</given-names>
</name>
<name>
<surname>García-Marín</surname>
<given-names>J. F.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Giant cell tumour of bone in a cat with extraskeletal metastases: Pathological and immunohistochemical study</article-title>. <source>J Vet Med A Physiol Pathol Clin Med</source> <volume>52</volume>, <fpage>225</fpage>–<lpage>29</lpage>.</citation>
</ref>
<ref id="bibr46-0192623311436186">
<citation citation-type="book">
<person-group person-group-type="author"><name><surname>Fornasier</surname><given-names>V. L.</given-names></name><name><surname>Protzner</surname><given-names>K.</given-names></name><name><surname>Zhang</surname><given-names>I.</given-names></name><name><surname>Mason</surname><given-names>L.</given-names></name></person-group> (<year>1996</year>). <article-title>The prognostic significance of histomorphometry and immunohistochemistry in giant cell tumors of bone</article-title>. <source>Hum Pathol</source> <volume>27</volume>, <fpage>754</fpage>–<lpage>60</lpage>.</citation></ref>
<ref id="bibr13-0192623311436186">
<citation citation-type="web">
<person-group person-group-type="author">
<name>
<surname>Forsyth</surname>
<given-names>R. G.</given-names>
</name>
<name>
<surname>Hogendoorn</surname>
<given-names>P. C. W</given-names>
</name>
</person-group>. (<year>2003</year>). <article-title>Bone: giant cell tumour</article-title>. In <source>Atlas Genet Cytogenet Oncol Haematol</source> (<person-group person-group-type="editor">
<name>
<surname>Huret</surname>
<given-names>J. L.</given-names>
</name>
</person-group>, ed.). <ext-link ext-link-type="uri" xlink:href="http://AtlasGeneticsOncology.org/Tumors/BoneGiantCellTumID5150.html">http://AtlasGeneticsOncology.org/Tumors/BoneGiantCellTumID5150.html</ext-link>. <comment>Accessed September 2011</comment>.</citation>
</ref>
<ref id="bibr14-0192623311436186">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Girardini</surname>
<given-names>J. E.</given-names>
</name>
<name>
<surname>Napoli</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Piazza</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Rustighi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Marotta</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Radaelli</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Capaci</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Jordan</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Quinlan</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mano</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rosato</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Crook</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Scanziani</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Means</surname>
<given-names>A. R.</given-names>
</name>
<name>
<surname>Lozano</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Del Sal</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Pin1/mutant p53 axis promotes aggressiveness in breast cancer</article-title>. <source>Cancer Cell</source> <volume>20</volume>, <fpage>79</fpage>–<lpage>91</lpage>.</citation>
</ref>
<ref id="bibr15-0192623311436186">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Imai</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hibino</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Hayakawa</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Nakanowatari</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Fukuta</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hosokawa</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sagami</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>1998</year>). <article-title>Giant cell tumor of bone in an aged Fischer 344 rat</article-title>. <source>Toxicol Pathol</source> <volume>26</volume>, <fpage>802</fpage>–<lpage>5</lpage>.</citation>
</ref>
<ref id="bibr16-0192623311436186">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jeong</surname>
<given-names>J. O.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>J. W.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>H. J.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>D. W.</given-names>
</name>
<name>
<surname>Yoon</surname>
<given-names>Y. S.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Malignant tumor formation after transplantation of short-term cultured bone marrow mesenchymal stem cells in experimental myocardial infarction and diabetic neuropathy</article-title>. <source>Circ Res</source> <volume>108</volume>, <fpage>1340</fpage>–<lpage>47</lpage>.</citation>
</ref>
<ref id="bibr17-0192623311436186">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kavirayani</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Foreman</surname>
<given-names>O.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Retrospective study of spontaneous osteosarcomas in the nonobese diabetic strain and nonobese diabetic-derived substrains of mice</article-title>. <source>Vet Pathol</source> <volume>47</volume>, <fpage>482</fpage>–<lpage>87</lpage>.</citation>
</ref>
<ref id="bibr18-0192623311436186">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kavirayani</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Sundberg</surname>
<given-names>J. P.</given-names>
</name>
<name>
<surname>Foreman</surname>
<given-names>O.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Primary neoplasms of bones in mice: Retrospective study and review of literature</article-title>. <source>Vet Pathol</source> <volume>49</volume>, <fpage>182</fpage>–<fpage>205</fpage>.</citation>
</ref>
<ref id="bibr19-0192623311436186">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lang</surname>
<given-names>G. A.</given-names>
</name>
<name>
<surname>Iwakuma</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Suh</surname>
<given-names>Y. A.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Rao</surname>
<given-names>V. A.</given-names>
</name>
<name>
<surname>Parant</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Valentin-Vega</surname>
<given-names>Y. A.</given-names>
</name>
<name>
<surname>Terzian</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Caldwell</surname>
<given-names>L. C.</given-names>
</name>
<name>
<surname>Strong</surname>
<given-names>L. C.</given-names>
</name>
<name>
<surname>El-Naggar</surname>
<given-names>A. K.</given-names>
</name>
<name>
<surname>Lozano</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome</article-title>. <source>Cell</source> <volume>119</volume>, <fpage>861</fpage>–<lpage>72</lpage>.</citation>
</ref>
<ref id="bibr20-0192623311436186">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liao</surname>
<given-names>T. S.</given-names>
</name>
<name>
<surname>Yurgelun</surname>
<given-names>M. B.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>S. S.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H. Z.</given-names>
</name>
<name>
<surname>Murakami</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Blaine</surname>
<given-names>T. A.</given-names>
</name>
<name>
<surname>Parisien</surname>
<given-names>M. V.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Winchester</surname>
<given-names>R. J.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>F. Y.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Recruitment of osteoclast precursors by stromal cell derived factor-1 (SDF-1) in giant cell tumor of bone</article-title>. <source>J Orthop Res</source> <volume>23</volume>, <fpage>203</fpage>–<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr21-0192623311436186">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>H. S.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J. W.</given-names>
</name>
</person-group> (<year>1998</year>). <article-title>Treatment of giant cell tumor of bone: A comparison of local curettage and wide resection</article-title>. <source>Changgeng Yi Xue ZA Zhi</source> <volume>21</volume>, <fpage>37</fpage>–<lpage>43</lpage>.</citation>
</ref>
<ref id="bibr22-0192623311436186">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mendenhall</surname>
<given-names>W. M.</given-names>
</name>
<name>
<surname>Zlotecki</surname>
<given-names>R. A.</given-names>
</name>
<name>
<surname>Scarborough</surname>
<given-names>M. T.</given-names>
</name>
<name>
<surname>Gibbs</surname>
<given-names>C. P.</given-names>
</name>
<name>
<surname>Mendenhall</surname>
<given-names>N. P.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Giant cell tumor of bone</article-title>. <source>Am J Clin Oncol</source> <volume>29</volume>, <fpage>96</fpage>–<lpage>99</lpage>.</citation>
</ref>
<ref id="bibr23-0192623311436186">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miyamoto</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Higuchi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Tajima</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tsurudome</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nishio</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kawano</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sudo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Uchida</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>Spindle-shaped cells derived from giant-cell tumor of bone support differentiation of blood monocytes to osteoclast-like cells</article-title>. <source>J Orthop Res</source> <volume>18</volume>, <fpage>647</fpage>–<lpage>54</lpage>.</citation>
</ref>
<ref id="bibr24-0192623311436186">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morgan</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Atkins</surname>
<given-names>G. J.</given-names>
</name>
<name>
<surname>Trivett</surname>
<given-names>M. K.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>S. A.</given-names>
</name>
<name>
<surname>Kansara</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Schlicht</surname>
<given-names>S. L.</given-names>
</name>
<name>
<surname>Slavin</surname>
<given-names>J. L.</given-names>
</name>
<name>
<surname>Simmons</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Dickinson</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Powell</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Choong</surname>
<given-names>P. F.</given-names>
</name>
<name>
<surname>Holloway</surname>
<given-names>A. J.</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>D. M.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappaB</article-title>. <source>Am J Pathol</source> <volume>167</volume>, <fpage>117</fpage>–<lpage>28</lpage>.</citation>
</ref>
<ref id="bibr25-0192623311436186">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Negrin</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bernardini</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Diana</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Castagnaro</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Giant cell osteosarcoma in the calvarium of a cat</article-title>. <source>Vet Pathol</source> <volume>43</volume>, <fpage>179</fpage>–<lpage>82</lpage>.</citation>
</ref>
<ref id="bibr26-0192623311436186">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oda</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sakamoto</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Saito</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Matsuda</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tanaka</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Iwamoto</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Tsuneyoshi</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>Secondary malignant giant-cell tumour of bone: Molecular abnormalities of p53 and H-ras gene correlated with malignant transformation</article-title>. <source>Histopathology</source> <volume>39</volume>, <fpage>629</fpage>–<lpage>37</lpage>.</citation>
</ref>
<ref id="bibr27-0192623311436186">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>O’Donnell</surname>
<given-names>R. J.</given-names>
</name>
<name>
<surname>Springfield</surname>
<given-names>D. S.</given-names>
</name>
<name>
<surname>Motwani</surname>
<given-names>H. K.</given-names>
</name>
<name>
<surname>Ready</surname>
<given-names>J. E.</given-names>
</name>
<name>
<surname>Gebhardt</surname>
<given-names>M. C.</given-names>
</name>
<name>
<surname>Mankin</surname>
<given-names>H. J.</given-names>
</name>
</person-group> (<year>1994</year>). <article-title>Recurrence of giant-cell tumors of the long bones after curettage and packing with cement</article-title>. <source>J Bone Joint Surg Am</source> <volume>76</volume>, <fpage>1827</fpage>–<lpage>33</lpage>.</citation>
</ref>
<ref id="bibr28-0192623311436186">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Reid</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Banerjee</surname>
<given-names>S. S.</given-names>
</name>
<name>
<surname>Sciot</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Giant cell tumor</article-title>. <source>In WHO Classification of Tumours: Pathology of Genetics of Tumors of Soft Tissue and Bone</source> (<person-group person-group-type="editor">
<name>
<surname>Fletcher</surname>
<given-names>C. D. M.</given-names>
</name>
<name>
<surname>Unni</surname>
<given-names>K. K.</given-names>
</name>
<name>
<surname>Mertens</surname>
<given-names>F.</given-names>
</name>
</person-group>, eds.), pp <fpage>311</fpage>–<lpage>312</lpage>. <publisher-name>IARC Scientific Publication</publisher-name>, <publisher-loc>Lyon, France</publisher-loc>.</citation>
</ref>
<ref id="bibr29-0192623311436186">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Robinson</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Segal</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nevo</surname>
<given-names>Z</given-names>
</name>
</person-group>. (<year>2002-2003</year>). <article-title>Giant cell tumor of bone: The role of fibroblast growth factor 3 positive mesenchymal stem cells in its pathogenesis</article-title>. <source>Pathobiology</source> <volume>70</volume>, <fpage>333</fpage>–<lpage>42</lpage>.</citation>
</ref>
<ref id="bibr30-0192623311436186">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roux</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Amazit</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Meduri</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Guiochon-Mantel</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Milgrom</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Mariette</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone</article-title>. <source>Am J Clin Pathol</source> <volume>117</volume>, <fpage>210</fpage>–<lpage>16</lpage>.</citation>
</ref>
<ref id="bibr31-0192623311436186">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salerno</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Avnet</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Alberghini</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Giunti</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Baldini</surname>
<given-names>N.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Histogenetic characterization of giant cell tumor of bone</article-title>. <source>Clin Orthop Relat Res</source> <volume>466</volume>, <fpage>2081</fpage>–<lpage>91</lpage>.</citation>
</ref>
<ref id="bibr32-0192623311436186">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sato</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Yamamura</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Iwata</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Sugiura</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Nakashima</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Nagasaka</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>1996</year>). <article-title>Giant cell-rich osteosarcoma: A case report</article-title>. <source>Nagoya J Med Sci</source> <volume>59</volume>, <fpage>151</fpage>–<lpage>57</lpage>.</citation>
</ref>
<ref id="bibr33-0192623311436186">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thomas</surname>
<given-names>D. M.</given-names>
</name>
<name>
<surname>Skubitz</surname>
<given-names>K. M.</given-names>
</name>
</person-group> (<year>2009</year>) <article-title>Giant cell tumour of bone</article-title>. <source>Curr Opin Oncol</source> <volume>21</volume>, <fpage>338</fpage>–<lpage>44</lpage>.</citation>
</ref>
<ref id="bibr34-0192623311436186">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trigo</surname>
<given-names>F. J.</given-names>
</name>
<name>
<surname>Leathers</surname>
<given-names>C. W.</given-names>
</name>
<name>
<surname>Brobst</surname>
<given-names>D. F.</given-names>
</name>
</person-group> (<year>1983</year>). <article-title>A comparison of canine giant cell tumor and giant cell reparative granuloma of bone</article-title>. <source>Vet Pathol</source> <volume>20</volume>, <fpage>215</fpage>–<lpage>22</lpage>.</citation>
</ref>
<ref id="bibr35-0192623311436186">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walsh</surname>
<given-names>B. A.</given-names>
</name>
<name>
<surname>Rhodes</surname>
<given-names>W. H.</given-names>
</name>
</person-group> (<year>1995</year>). <article-title>Giant cell tumour of bone in a cat</article-title>. <source>J Small Anim Pract</source> <volume>36</volume>, <fpage>325</fpage>–<lpage>29</lpage>.</citation>
</ref>
<ref id="bibr36-0192623311436186">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Watanabe</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Tajino</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kusakabe</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Saitoh</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>1997</year>). <article-title>Giant cell tumor of bone: Frequent actin immunoreactivity in stromal tumor cells</article-title>. <source>Pathol Int</source> <volume>47</volume>, <fpage>680</fpage>–<lpage>84</lpage>.</citation>
</ref>
<ref id="bibr37-0192623311436186">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Watanabe</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Tajino</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Sekiguchi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>T</given-names>
</name>
</person-group>. (<year>2000</year>). <article-title>h-Caldesmon as a specific marker for smooth muscle tumors: Comparison with other smooth muscle markers in bone tumors</article-title>. <source>Am J Clin Pathol</source> <volume>113</volume>, <fpage>663</fpage>–<lpage>68</lpage>.</citation>
</ref>
<ref id="bibr38-0192623311436186">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Werner</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Giant cell tumour of bone: Morphological, biological and histogenetical aspects</article-title>. <source>Int Orthop</source> <volume>30</volume>, <fpage>484</fpage>–<lpage>89</lpage>.</citation>
</ref>
<ref id="bibr39-0192623311436186">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wilson</surname>
<given-names>J. T.</given-names>
</name>
<name>
<surname>Hauser</surname>
<given-names>R. E.</given-names>
</name>
<name>
<surname>Ryffel</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>1985</year>). <article-title>Osteomas in OF-1 mice: No alteration in biologic behavior during long-term treatment with cyclosporine</article-title>. <source>J Natl Cancer Inst</source> <volume>75</volume>, <fpage>897</fpage>–<lpage>903</lpage>.</citation>
</ref>
<ref id="bibr40-0192623311436186">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Hsiu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Somers</surname>
<given-names>K</given-names>
</name>
</person-group>. (<year>1997</year>). <article-title>p53 protein accumulation and genetic alterations in human giant cell tumors of bone (osteoclastomas)</article-title>. <source>Int J Oncol</source> <volume>10</volume>, <fpage>1087</fpage>–<lpage>92</lpage>.</citation>
</ref>
<ref id="bibr41-0192623311436186">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wülling</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Delling</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Kaiser</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>The origin of the neoplastic stromal cell in giant cell tumor of bone</article-title>. <source>Hum Pathol</source> <volume>34</volume>, <fpage>983</fpage>–<lpage>93</lpage>.</citation>
</ref>
<ref id="bibr42-0192623311436186">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wülling</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Engels</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Jesse</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Werner</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Delling</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Kaiser</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>The nature of giant cell tumor of bone</article-title>. <source>J Cancer Res Clin Oncol</source> <volume>127</volume>, <fpage>467</fpage>–<lpage>74</lpage>.</citation>
</ref>
<ref id="bibr43-0192623311436186">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yasko</surname>
<given-names>A. W.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Giant cell tumor of bone</article-title>. <source>Curr Oncol Rep</source> <volume>4</volume>, <fpage>520</fpage>–<lpage>26</lpage>.</citation>
</ref>
<ref id="bibr44-0192623311436186">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zheng</surname>
<given-names>M. H.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wysocki</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Papadimitriou</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Wood</surname>
<given-names>D. J.</given-names>
</name>
</person-group> (<year>1998</year>). <article-title>Gene expression of monocyte chemoattractant protein-1 in giant cell tumors of bone osteoclastoma: Possible involvement in CD68+ macrophage-like cell migration</article-title>. <source>J Cell Biochem</source> <volume>70</volume>, <fpage>121</fpage>–<lpage>29</lpage>.</citation>
</ref>
<ref id="bibr45-0192623311436186">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zheng</surname>
<given-names>M. H.</given-names>
</name>
<name>
<surname>Robbins</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wood</surname>
<given-names>D. J.</given-names>
</name>
<name>
<surname>Papadimitriou</surname>
<given-names>J. M.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>The histogenesis of giant cell tumour of bone: A model of interaction between neoplastic cells and osteoclasts</article-title>. <source>Histol Histopathol</source> <volume>16</volume>, <fpage>297</fpage>–<lpage>307</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>